Biodesix, Inc. (Biodesix) is a diagnostic solutions and services company. The Company develops diagnostic tests addressing clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix offers over five Medicare-covered tests for patients with lung diseases. The blood based Nodify Lung Nodule Risk Assessment testing strategy, consisting of the Nodify XL2 and the Nodify CDT tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the appropriate course of action. The blood based IQLung strategy for lung cancer patients integrates the GeneStrat targeted ddPCR test, the GeneStrat NGS test and the VeriStrat test to support treatment decisions across all stages of lung cancer. Biodesix also leverages the advanced Diagnostic Cortex artificial intelligence (AI) platform, to collaborate with biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease.
BörsenkürzelBDSX
Name des UnternehmensBiodesix Inc
IPO-datumOct 28, 2020
CEOMr. Scott Hutton
Anzahl der mitarbeiter273
WertpapierartOrdinary Share
GeschäftsjahresendeOct 28
Addresse919 West Dillon Road
StadtLOUISVILLE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl80027
Telefon13034170500
Websitehttps://www.biodesix.com/
BörsenkürzelBDSX
IPO-datumOct 28, 2020
CEOMr. Scott Hutton
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten